Mechano-energetic efficiency in patients with hypertrophic cardiomyopathy with and without sarcomeric mutations.
Hypertrophic cardiomyopathy
Mechano-energetic
Non-sarcomeric HCM
Sarcomeric HCM
Journal
Journal of cardiovascular translational research
ISSN: 1937-5395
Titre abrégé: J Cardiovasc Transl Res
Pays: United States
ID NLM: 101468585
Informations de publication
Date de publication:
13 Oct 2023
13 Oct 2023
Historique:
received:
21
06
2023
accepted:
18
09
2023
medline:
14
10
2023
pubmed:
14
10
2023
entrez:
13
10
2023
Statut:
aheadofprint
Résumé
Hypertrophic cardiomyopathy (HCM) is mainly caused by sarcomeric mutations which may affect myocardial mechano-energetic efficiency (MEE). We investigated the effects of sarcomeric mutations on MEE. A non-invasive pressure/volume (P/V) analysis was performed. We included 49 genetically screened HCM patients. MEEi was calculated as the ratio between stroke volume and heart rate normalized by LV mass. Fifty-seven percent (57%) HCM patients carried a sarcomeric mutation. Patients with and without sarcomeric mutations had similar LV ejection fraction, heart rate, LV mass, and LV outflow gradient. Younger age at diagnosis, family history of HCM, and lower MEEi were associated with presence of sarcomeric mutation (p = 0.017; p = 0.001 and p = 0.0001, respectively). Lower MEEi in HCM with sarcomeric mutation is not related to significant differences on filling pressure as shown on P/V analysis. Sarcomeric mutations determine a reduction of the LV pump performance as estimated by MEEi in HCM. Lower MEEi may predict a positive genetic analysis.
Identifiants
pubmed: 37833437
doi: 10.1007/s12265-023-10441-2
pii: 10.1007/s12265-023-10441-2
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB. Contemporary definitions and classification of the cardiomyopathies. Circulation. 2006;113(14):1807–16. https://doi.org/10.1161/CIRCULATIONAHA.106.174287 .
doi: 10.1161/CIRCULATIONAHA.106.174287
pubmed: 16567565
Elliott PM, Anastasakis A, Borger MA, Borggrefe M, Cecchi F, Scharron P, Hagege AA, Lofont A, Limongelli G, Mahrholdt H, et al. 2014 ESC guidelines on diagnosis and management of hypertrophic cardiomyopathy. Eur Heart J. 2014;35(39):2733–79. https://doi.org/10.1093/eurheartj/ehu284 .
doi: 10.1093/eurheartj/ehu284
pubmed: 25173338
Maron BJ, Desai MY, Nishimura RA, Spirito P, Rakowski H, Towbin JA, Rowin EJ, Maron MS, Sherrid MV. Diagnosis and evaluation of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2022;79(4):372–89. https://doi.org/10.1016/j.jacc.2021.12.002 .
doi: 10.1016/j.jacc.2021.12.002
pubmed: 35086660
Moody WE, Elliott PM. Changing concepts in heart muscle disease: the evolving understanding of hypertrophic cardiomyopathy. Heart. 2022;108(10):768–73. https://doi.org/10.1136/heartjnl-2021-320145 .
doi: 10.1136/heartjnl-2021-320145
pubmed: 35459726
Nagueh S, Chen S, Patel R, Tsybouleva N, Lutucuta S, Kopelen HA, Zoghbi WA, Quiñones MA, Roberts R, Marian AJ. Evolution of expression of cardiac phenotypes over a 4-year period in the b -myosin heavy chain-Q403 transgenic rabbit model of human hypertrophic cardiomyopathy. J Mol Cell Cardiol. 2004;36(5):663–73. https://doi.org/10.1016/j.yjmcc.2004.02.010 .
doi: 10.1016/j.yjmcc.2004.02.010
pubmed: 15135661
pmcid: 2768620
Marian AJ, Braunwald E. Hypertrophic cardiomyopathy. Circ Res. 2017;121(7):749–70. https://doi.org/10.1161/CIRCRESAHA.117.311059 .
doi: 10.1161/CIRCRESAHA.117.311059
pubmed: 28912181
pmcid: 5654557
Luedde M, Flögel U, Knorr M, Grundt C, Hippe H-J, Brors B, Frank D, Haselmann U, Antony C, Voelkers M, et al. Decreased contractility due to energy deprivation in a transgenic rat model of hypertrophic cardiomyopathy. J Mol Med. 2009;87(4):411–22. https://doi.org/10.1007/s00109-008-0436-x .
doi: 10.1007/s00109-008-0436-x
pubmed: 19189074
Jung W-I, Sieverding L, Breuer J, Hoess T, Widmaier S, Schmidt O, Bunse M, van Erckelens F, Apitz J, Lutz O, et al.
doi: 10.1161/01.CIR.97.25.2536
pubmed: 9657474
Juszczyk A, Jankowska K, Zawiślak B, Surdacki A, Chyrchel B. Depressed cardiac mechanical energetic efficiency: a contributor to cardiovascular risk in common metabolic diseases—from mechanisms to clinical applications. J Clin Med. 2020;9(9):2681. https://doi.org/10.3390/jcm9092681 .
doi: 10.3390/jcm9092681
pubmed: 32824903
pmcid: 7565585
de Simone G, Chinali M, Galderisi M, Benincasa M, Girfoglio D, Botta I, D’Addeo G, de Divitiis O. Myocardial mechano-energetic efficiency in hypertensive adults. J Hypertens. 2009;27(3):650–5. https://doi.org/10.1097/HJH.0b013e328320ab97 .
doi: 10.1097/HJH.0b013e328320ab97
pubmed: 19330923
Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P, McKenna WJ, Östman-Smith I, Clarke K, Watkins H. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol. 2003;41(10):1776–82. https://doi.org/10.1016/S0735-1097(02)03009-7 .
doi: 10.1016/S0735-1097(02)03009-7
pubmed: 12767664
Bastos MB, Burkhoff D, Maly J, Daemen J, den Uil CA, Ameloot K, Lenzen M, Mahfoud F, Zijlstra F, Schreuder JJ, et al. Invasive left ventricle pressure–volume analysis: overview and practical clinical implications. Eur Heart J. 2020;41(12):1286–97. https://doi.org/10.1093/eurheartj/ehz552 .
doi: 10.1093/eurheartj/ehz552
pubmed: 31435675
Burkhoff D, Mirsky I, Suga H. Assessment of systolic and diastolic ventricular properties via pressure-volume analysis: a guide for clinical, translational, and basic researchers. Am J Physiol-Heart Circulatory Physiol. 2005;289(2):H501–12. https://doi.org/10.1152/ajpheart.00138.2005 .
doi: 10.1152/ajpheart.00138.2005
World Medical Association. Declaration of Helsinki. JAMA. 2013;310(20):2191. https://doi.org/10.1001/jama.2013.281053 .
doi: 10.1001/jama.2013.281053
Maurizi N, Rella V, Fumagalli C, Salerno S, Castelletti S, Dagradi F, Torchio M, Marceca A, Meda M, Gasparini M, et al. Prevalence of cardiac amyloidosis among adult patients referred to tertiary centres with an initial diagnosis of hypertrophic cardiomyopathy. Int J Cardiol. 2020;300:191–5. https://doi.org/10.1016/j.ijcard.2019.07.051 .
doi: 10.1016/j.ijcard.2019.07.051
pubmed: 31371117
Mazzaccara C, Lombardi R, Mirra B, Barretta F, Esposito MV, Uomo F, Caiazza M, Monda E, Losi MA, Limongelli G, et al. Next-generation sequencing gene panels in inheritable cardiomyopathies and channelopathies: prevalence of pathogenic variants and variants of unknown significance in uncommon genes. Biomolecules. 2022;12(10):1417. https://doi.org/10.3390/biom12101417 .
doi: 10.3390/biom12101417
pubmed: 36291626
pmcid: 9599286
Richards S, Aziz N, Bale S, Bick D, Das S, Gastier-Foster J, Grody WW, Hegde M, Lyon E, Spector E, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. Genet Med. 2015;17(5):405–24. https://doi.org/10.1038/gim.2015.30 .
doi: 10.1038/gim.2015.30
pubmed: 25741868
pmcid: 4544753
Hershberger RE, Givertz MM, Ho CY, Judge DP, Kantor PF, McBride KL, Morales A, Taylor MRG, Vatta M, Ware SM. Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG). Genet Med. 2018;20(9):899–909. https://doi.org/10.1038/s41436-018-0039-z .
doi: 10.1038/s41436-018-0039-z
pubmed: 29904160
Betocchi S, Piscione F, Losi MA, Pace L, Boccalatte M, Perrone-Filardi P, Cappelli-Bigazzi M, Briguori C, Manganelli F, Ciampi Q, et al. Effects of diltiazem on left ventricular systolic and diastolic function in hypertrophic cardiomyopathy. Am J Cardiol. 1996;78(4):451–7. https://doi.org/10.1016/s0002-9149(96)00336-0 .
doi: 10.1016/s0002-9149(96)00336-0
pubmed: 8752192
Pollick C, Morgan CD, Gilbert BW, Rakowski H, Wigle ED. Muscular subaortic stenosis: the temporal relationship between systolic anterior motion of the anterior mitral leaflet and the pressure gradient. Circulation. 1982;66(5):1087–94. https://doi.org/10.1161/01.CIR.66.5.1087 .
doi: 10.1161/01.CIR.66.5.1087
pubmed: 7127693
Panza JA, Maris TJ, Maron BJ. Development and determinants of dynamic obstruction to left ventricular outflow in young patients with hypertrophic cardiomyopathy. Circulation. 1992;85(4):1398–405. https://doi.org/10.1161/01.CIR.85.4.1398 .
doi: 10.1161/01.CIR.85.4.1398
pubmed: 1555282
Vanoverschelde JL, Wijns W, Essamri B, Bol A, Robert A, Labar D, Cogneau M, Michel C, Melin JA. Hemodynamic and mechanical determinants of myocardial O2 consumption in normal human heart: effects of dobutamine. Am J Physiol-Heart Circulatory Physiol. 1993;265(6):H1884–92. https://doi.org/10.1152/ajpheart.1993.265.6.H1884 .
doi: 10.1152/ajpheart.1993.265.6.H1884
Losi MA, Izzo R, Mancusi C, Wang W, Roman MJ, Lee ET, Howard BV, Devereux RB, de Simone G. Depressed myocardial energetic efficiency increases risk of incident heart failure: the Strong Heart Study. J Clin Med. 2019;8(7):1044. https://doi.org/10.3390/jcm8071044 .
doi: 10.3390/jcm8071044
pubmed: 31319598
pmcid: 6678469
de Simone G, Izzo R, Losi MA, Stabile E, Rozza F, Canciello G, Mancusi C, Trimarco V, De Luca N, Trimarco B. Depressed myocardial energetic efficiency is associated with increased cardiovascular risk in hypertensive left ventricular hypertrophy. J Hypertens. 2016;34(9):1846–53. https://doi.org/10.1097/HJH.0000000000001007 .
doi: 10.1097/HJH.0000000000001007
pubmed: 27367264
Mancusi C, Losi MA, Izzo R, Canciello G, Manzi MV, Sforza A, De Luca N, Trimarco B, de Simone G. Effect of diabetes and metabolic syndrome on myocardial mechano-energetic efficiency in hypertensive patients. The Campania Salute Network. J Hum Hypertens. 2017;31:395–9. https://doi.org/10.1038/jhh.2016.88 .
doi: 10.1038/jhh.2016.88
pubmed: 28032631
Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, Reichek N. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57(6):450–8. https://doi.org/10.1016/0002-9149(86)90771-X.
doi: 10.1016/0002-9149(86)90771-X.
pubmed: 2936235
Losi MA, Imbriaco M, Canciello G, Pacelli F, Di Nardo C, Lombardi R, Izzo R, Mancusi C, Ponsiglione A, Dell’Aversana S, et al. Left ventricular mass in hypertrophic cardiomyopathy assessed by 2D-echocardiography: validation with magnetic resonance imaging. J Cardiovasc Transl Res. 2020;13(2):238–44. https://doi.org/10.1007/s12265-019-09911-3 .
doi: 10.1007/s12265-019-09911-3
pubmed: 31489577
Cioffi G, Battiston R, Mancusi C, Di Lenarda A, Faganello G, Aurigemma GP, Tarantini L, Pulignano G, Cioffi V, de Simone G. Prognostic stratification of clinically stable patients with heart failure by echocardiographic pressure/volume loop model. J Am Soc Echocardiography. 2023; https://doi.org/10.1016/j.echo.2023.02.006 .
Ferrara F, Capone V, Cademartiri F, Vriz O, Cocchia R, Ranieri B, Franzese M, Castaldo R, D’Andrea A, Citro R, et al. Physiologic range of myocardial mechano-energetic efficiency among healthy subjects: impact of gender and age. J Pers Med. 2022;12(6):996. https://doi.org/10.3390/jpm12060996 .
doi: 10.3390/jpm12060996
pubmed: 35743780
pmcid: 9224845
Ingles J, Goldstein J, Thaxton C, Caleshu C, Corty EW, Crowley SB, Dougherty K, Harriso SM, McGlaughon J, Milko LV, et al. Evaluating the clinical validity of hypertrophic cardiomyopathy genes. Circ Genom Precis Med. 2019;12(2):e002460. https://doi.org/10.1161/CIRCGEN.119.002460 .
doi: 10.1161/CIRCGEN.119.002460
pubmed: 30681346
pmcid: 6410971
Walsh R, Offerhaus JA, Tadros R, Bezzina CR. Minor hypertrophic cardiomyopathy genes, major insights into the genetics of cardiomyopathies. Nat Rev Cardiol. 2022;19(3):151–67. https://doi.org/10.1038/s41569-021-00608-2 .
doi: 10.1038/s41569-021-00608-2
pubmed: 34526680
Grossman W, Jones D, McLaurin LP. Wall stress and patterns of hypertrophy in the human left ventricle. J Clin Invest. 1975;56(1):56–64. https://doi.org/10.1172/JCI108079 .
doi: 10.1172/JCI108079
pubmed: 124746
pmcid: 436555
Lankford EB, Epstein ND, Fananapazir L, Sweeney HL. Abnormal contractile properties of muscle fibers expressing beta-myosin heavy chain gene mutations in patients with hypertrophic cardiomyopathy. J Clin Invest. 1995;95(3):1409–14. https://doi.org/10.1172/JCI117795 .
doi: 10.1172/JCI117795
pubmed: 7883988
pmcid: 441484
Maron MS. Clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14(1):13. https://doi.org/10.1186/1532-429X-14-13 .
doi: 10.1186/1532-429X-14-13
pubmed: 22296938
pmcid: 3293092
Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy: a paradigm for myocardial energy depletion. Trends Genet. 2003;19(5):263–8. https://doi.org/10.1016/S0168-9525(03)00081-7 .
doi: 10.1016/S0168-9525(03)00081-7
pubmed: 12711218
Witjas-Paalberends ER, Güçlü A, Germans T, Knaapen P, Harms HJ, Vermeer AMC, Christiaans I, Wilde AAM, Dos Remedios C, Lammertsma AA, et al. Gene-specific increase in the energetic cost of contraction in hypertrophic cardiomyopathy caused by thick filament mutations. Cardiovasc Res. 2014;103(2):248–57. https://doi.org/10.1093/cvr/cvu127 .
doi: 10.1093/cvr/cvu127
pubmed: 24835277
Neubauer S, Kolm P, Ho CY, Kwong RY, Desai MY, Dolman SF, Appelbaum E, Desvigne-Nickens P, DiMarco JP, Friedrich MG, et al. Distinct subgroups in hypertrophic cardiomyopathy in the NHLBI HCM Registry. J Am Coll Cardiol. 2019;74(19):2333–45. https://doi.org/10.1016/j.jacc.2019.08.1057 .
doi: 10.1016/j.jacc.2019.08.1057
pubmed: 31699273
pmcid: 6905038
Watkins H. Time to think differently about sarcomere-negative hypertrophic cardiomyopathy. Circulation. 2021;143(25):2415–7. https://doi.org/10.1161/CIRCULATIONAHA.121.053527 .
doi: 10.1161/CIRCULATIONAHA.121.053527
pubmed: 34152793
Harper AR, Goel A, Grace C, Thomson KL, Petersen SE, Xu X, Waring A, Ormondroyd E, Kramer CM, Ho CY, et al. Common genetic variants and modifiable risk factors underpin hypertrophic cardiomyopathy susceptibility and expressivity. Nat Genet. 2021;53(2):135–42. https://doi.org/10.1038/s41588-020-00764-0 .
doi: 10.1038/s41588-020-00764-0
pubmed: 33495597
pmcid: 8240954
Sweeney HL, Feng HS, Yang Z, Watkins H. Functional analyses of troponin T mutations that cause hypertrophic cardiomyopathy: insights into disease pathogenesis and troponin function. Pro Nat Acad Sci. 1998;95(24):14406–10. https://doi.org/10.1073/pnas.95.24.14406 .
doi: 10.1073/pnas.95.24.14406
Wang Y, Zhang L, Liu J, Yue X, Shi H, Li Y, Xie M, Lv Q. Automated three-dimensional echocardiographic quantification for left ventricular volume and function in patients with hypertrophic cardiomyopathy. Echocardiography. 2022;39(5):658–66. https://doi.org/10.1111/echo.15322 .
doi: 10.1111/echo.15322
pubmed: 35347747